Published in Cancer Weekly, April 17th, 2006
Harris has extensive pharmaceutical industry knowledge and experience in clinical development and the regulatory approval process, particularly in the area of oncology. Prior to joining VioQuest, Harris was chief medical officer at Callisto Pharmaceuticals, Inc. She was previously senior medical director for Pfizer, where she was responsible for U.S. development of Aromasin, an aromatase inhibitor for breast cancer, and Epirubicin, an anthracycline for adjuvant chemotherapy of breast cancer.
Prior to Pfizer, Harris held positions in clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.